Status:
RECRUITING
Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Status Epilepticus
Dysimmune Encephalopathy
Eligibility:
All Genders
2+ years
Phase:
NA
Brief Summary
COLETTE is an interventional study for which blood, cerebrospinal fluid and post-mortem tissues are collected in patients with status epilepticus or epilepsy associated to dysimmune encephalitis as we...
Detailed Description
Epilepsy is one of the most common neurological condition which concerns around 50 million people worldwide. Epilepsy is characterized by a lasting predisposition to generate seizures. Epilepsy can pr...
Eligibility Criteria
Inclusion
- Group 1:
- Patients aged 2 years or above, with status epilepticus.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients under legal protection (guardianship, curatorship) or not
- Group 2:
- Patients aged 2 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients under legal protection (guardianship, curatorship) or not
- Group 3:
- Patients aged 18 years or above, without status epilepticus and/or dysimmune encephalitis.
- Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
- Patients or relatives have been informed and given free informed and written consent to participate
- Patients under legal protection (guardianship, curatorship) or not
Exclusion
- Group 1:
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
- Patients with known neurodegenerative disease.
- Group 2:
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty
- Patients have been already treated by corticoids or IgIV.
- Group 3:
- Women with known or clinically detected pregnancy.
- Patient deprived of liberty.
- Patients with status epilepticus.
- Patients with known neurodegenerative disease, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhages, stroke.
Key Trial Info
Start Date :
November 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04421846
Start Date
November 25 2020
End Date
June 1 2027
Last Update
February 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital de la Pitié Salpêtrière
Paris, France, 75013